loading...| Preferred Name |
Myasthenia gravis |
|
| Synonyms |
Autoimmune myasthenia gravis |
|
| Definitions |
Myasthenia gravis (MG) is a rare, clinically heterogeneous, autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles. |
|
| ID |
http://www.orpha.net/ORDO/Orphanet_589 |
|
| alternative_term |
Autoimmune myasthenia gravis Acquired myasthenia |
|
| definition |
Myasthenia gravis (MG) is a rare, clinically heterogeneous, autoimmune disorder of the neuromuscular junction characterized by fatigable weakness of voluntary muscles. |
|
| definition_citation |
Orphanet |
|
| expertlink |
https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=589 |
|
| has_age_of_onset |
All ages |
|
| has_inheritance |
Not applicable Multigenic/multifactorial |
|
| hasDbXref |
OMIM:159400 ICD-11:8C60 ICD-10:G70.0 MedDRA:10028417 OMIM:607085 UMLS:C0026896 OMIM:254200 MeSH:D009157 |
|
| label |
Myasthenia gravis |
|
| notation |
ORPHA:589 |
|
| part_of | ||
| prefixIRI |
ORDO:Orphanet_589 |
|
| prefLabel |
Myasthenia gravis |
|
| present_in |
Austria AND has_point_prevalence_average_value : 15.7 AND has_point_prevalence_range : 1-5 / 10 000 Spain AND has_annual_incidence_average_value : 2.1 AND has_annual_incidence_range : 1-9 / 100 000 Worldwide AND has_point_prevalence_average_value : 7.77 AND has_point_prevalence_range : 1-9 / 100 000 Estonia AND has_point_prevalence_average_value : 7.8 AND has_point_prevalence_range : 1-9 / 100 000 Australia AND has_point_prevalence_average_value : 11.7 AND has_point_prevalence_range : 1-5 / 10 000 Croatia AND has_annual_incidence_average_value : 0.65 AND has_annual_incidence_range : 1-9 / 1 000 000 Serbia AND has_annual_incidence_average_value : 1.33 AND has_annual_incidence_range : 1-9 / 100 000 Greece AND has_annual_incidence_average_value : 0.74 AND has_annual_incidence_range : 1-9 / 1 000 000 Canada AND has_point_prevalence_average_value : 20.0 AND has_point_prevalence_range : 1-5 / 10 000 Europe AND has_point_prevalence_average_value : 20.0 AND has_point_prevalence_range : 1-5 / 10 000 Serbia AND has_point_prevalence_average_value : 31.8 AND has_point_prevalence_range : 1-5 / 10 000 United Kingdom AND has_point_prevalence_average_value : 15.0 AND has_point_prevalence_range : 1-5 / 10 000 Worldwide AND has_annual_incidence_average_value : 0.53 AND has_annual_incidence_range : 1-9 / 1 000 000 Australia AND has_annual_incidence_average_value : 2.5 AND has_annual_incidence_range : 1-9 / 100 000 Europe AND has_annual_incidence_average_value : 1.7 AND has_annual_incidence_range : 1-9 / 100 000 United States AND has_point_prevalence_average_value : 17.0 AND has_point_prevalence_range : 1-5 / 10 000 United Kingdom AND has_lifetime_prevalence_average_value : 40.0 AND has_lifetime_prevalence_range : 1-5 / 10 000 United Kingdom AND has_annual_incidence_average_value : 1.11 AND has_annual_incidence_range : 1-9 / 100 000 Taiwan, Province of China AND has_annual_incidence_average_value : 2.1 AND has_annual_incidence_range : 1-9 / 100 000 Italy AND has_point_prevalence_average_value : 18.5 AND has_point_prevalence_range : 1-5 / 10 000 Croatia AND has_point_prevalence_average_value : 9.9 AND has_point_prevalence_range : 1-9 / 100 000 Greece AND has_point_prevalence_average_value : 7.1 AND has_point_prevalence_range : 1-9 / 100 000 Egypt AND has_point_prevalence_average_value : 3.2 AND has_point_prevalence_range : 1-9 / 100 000 United States AND has_annual_incidence_average_value : 0.9 AND has_annual_incidence_range : 1-9 / 1 000 000 Italy AND has_annual_incidence_average_value : 1.94 AND has_annual_incidence_range : 1-9 / 100 000 Taiwan, Province of China AND has_point_prevalence_average_value : 14.0 AND has_point_prevalence_range : 1-5 / 10 000 |
|
| treeView | ||
| subClassOf |